The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency

LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Clinical criteria, protein det...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 137; no. 1; pp. 223 - 230
Main Authors Gámez-Díaz, Laura, August, Dietrich, Stepensky, Polina, Revel-Vilk, Shoshana, Seidel, Markus G., Noriko, Mitsuiki, Morio, Tomohiro, Worth, Austen J.J., Blessing, Jacob, Van de Veerdonk, Frank, Feuchtinger, Tobias, Kanariou, Maria, Schmitt-Graeff, Annette, Jung, Sophie, Seneviratne, Suranjith, Burns, Siobhan, Belohradsky, Bernd H., Rezaei, Nima, Bakhtiar, Shahrzad, Speckmann, Carsten, Jordan, Michael, Grimbacher, Bodo
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2016
Elsevier Limited
Elsevier
Subjects
Online AccessGet full text
ISSN0091-6749
1097-6825
1097-6825
DOI10.1016/j.jaci.2015.09.025

Cover

Loading…
Abstract LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.
AbstractList Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. Objective We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. Conclusion This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.
LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.
Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations inLRBAthat abolish LRBA protein expression. Objective We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results Ninety-three patients met the inclusion criteria and were considered to havepossibleLRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as havingprobableLRBA deficiency, whereas 22 were genetically confirmed as havingdefinitiveLRBA deficiency, with biallelic mutations inLRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. Conclusion This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.
Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. Objective We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA . Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents. Conclusion This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.
LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression.BACKGROUNDLPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression.We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients.OBJECTIVEWe sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients.Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency.METHODSClinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency.Ninety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents.RESULTSNinety-three patients met the inclusion criteria and were considered to have possible LRBA deficiency. Twenty-four patients did not express LRBA protein and were labeled as having probable LRBA deficiency, whereas 22 were genetically confirmed as having definitive LRBA deficiency, with biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T-cell counts, 73% had reduced regulatory T (Treg) cell numbers. Most LRBA-deficient patients had low B-cell subset counts, mainly in switched memory B cells (80%) and plasmablasts (92%), with a defective specific antibody response in 67%. Of the 22 patients, 3 are deceased, 2 were treated successfully with hematopoietic stem cell transplantation, 7 are receiving immunoglobulin replacement, and 15 are receiving immunosuppressive treatment with systemic corticosteroids alone or in combination with steroid-sparing agents.This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.CONCLUSIONThis report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting appropriate clinical management.
Author Seneviratne, Suranjith
Feuchtinger, Tobias
Burns, Siobhan
Jordan, Michael
Jung, Sophie
Noriko, Mitsuiki
Kanariou, Maria
Stepensky, Polina
Worth, Austen J.J.
Blessing, Jacob
Van de Veerdonk, Frank
Rezaei, Nima
Grimbacher, Bodo
Belohradsky, Bernd H.
Revel-Vilk, Shoshana
Speckmann, Carsten
Schmitt-Graeff, Annette
Gámez-Díaz, Laura
Bakhtiar, Shahrzad
Morio, Tomohiro
August, Dietrich
Seidel, Markus G.
Author_xml – sequence: 1
  givenname: Laura
  surname: Gámez-Díaz
  fullname: Gámez-Díaz, Laura
  organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
– sequence: 2
  givenname: Dietrich
  surname: August
  fullname: August, Dietrich
  organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
– sequence: 3
  givenname: Polina
  surname: Stepensky
  fullname: Stepensky, Polina
  organization: Pediatric Hematology-Oncology and Bone Marrow Transplantation, Hadassah Hebrew University Hospital, Jerusalem, Israel
– sequence: 4
  givenname: Shoshana
  surname: Revel-Vilk
  fullname: Revel-Vilk, Shoshana
  organization: Pediatric Hematology-Oncology and Bone Marrow Transplantation, Hadassah Hebrew University Hospital, Jerusalem, Israel
– sequence: 5
  givenname: Markus G.
  surname: Seidel
  fullname: Seidel, Markus G.
  organization: Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology-Oncology, Medical University Graz, Graz, Austria
– sequence: 6
  givenname: Mitsuiki
  surname: Noriko
  fullname: Noriko, Mitsuiki
  organization: Department of Pediatrics and Developmental Biology Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University, Tokyo, Japan
– sequence: 7
  givenname: Tomohiro
  surname: Morio
  fullname: Morio, Tomohiro
  organization: Department of Pediatrics and Developmental Biology Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University, Tokyo, Japan
– sequence: 8
  givenname: Austen J.J.
  surname: Worth
  fullname: Worth, Austen J.J.
  organization: Department of Immunology, Great Ormond Street Hospital for Children, London, United Kingdom
– sequence: 9
  givenname: Jacob
  surname: Blessing
  fullname: Blessing, Jacob
  organization: Cincinnati Children's Hospital Medical Center, University of Cincinnati Medical School, Cincinnati, Ohio
– sequence: 10
  givenname: Frank
  surname: Van de Veerdonk
  fullname: Van de Veerdonk, Frank
  organization: Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
– sequence: 11
  givenname: Tobias
  orcidid: 0000-0003-1509-8103
  surname: Feuchtinger
  fullname: Feuchtinger, Tobias
  organization: Pediatric Hematology, Oncology and Stem Cell Transplantation, Dr. von Hauner University Children's Hospital, Ludwig-Maximilians-Universität, Munich, Germany
– sequence: 12
  givenname: Maria
  surname: Kanariou
  fullname: Kanariou, Maria
  organization: Department of Immunology, “Aghia Sophia” Children's Hospital, Athens, Greece
– sequence: 13
  givenname: Annette
  surname: Schmitt-Graeff
  fullname: Schmitt-Graeff, Annette
  organization: Department of Pathology, University Hospital Freiburg, Freiburg, Germany
– sequence: 14
  givenname: Sophie
  surname: Jung
  fullname: Jung, Sophie
  organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
– sequence: 15
  givenname: Suranjith
  surname: Seneviratne
  fullname: Seneviratne, Suranjith
  organization: UCL Centre for Immunodeficiency, Royal Free Hospital Foundation Trust, London, United Kingdom
– sequence: 16
  givenname: Siobhan
  surname: Burns
  fullname: Burns, Siobhan
  organization: UCL Centre for Immunodeficiency, Royal Free Hospital Foundation Trust, London, United Kingdom
– sequence: 17
  givenname: Bernd H.
  surname: Belohradsky
  fullname: Belohradsky, Bernd H.
  organization: Division of Immunology and Infectious Disease, University Childrens Hospital Munich, Munich, Germany
– sequence: 18
  givenname: Nima
  surname: Rezaei
  fullname: Rezaei, Nima
  organization: Research Center for Immunodeficiencies, Children's Medical Center, and the Department of Immunology, School of Medicine Tehran University of Medical Sciences, Tehran, Iran
– sequence: 19
  givenname: Shahrzad
  surname: Bakhtiar
  fullname: Bakhtiar, Shahrzad
  organization: Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany
– sequence: 20
  givenname: Carsten
  surname: Speckmann
  fullname: Speckmann, Carsten
  organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
– sequence: 21
  givenname: Michael
  surname: Jordan
  fullname: Jordan, Michael
  organization: Cincinnati Children's Hospital Medical Center, University of Cincinnati Medical School, Cincinnati, Ohio
– sequence: 22
  givenname: Bodo
  surname: Grimbacher
  fullname: Grimbacher, Bodo
  email: bodo.grimbacher@uniklinik-freiburg.de
  organization: Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26768763$$D View this record in MEDLINE/PubMed
https://hal.science/hal-03417878$$DView record in HAL
BookMark eNqFkltvEzEQhS1URC_wB3hAK_HSPmzwZdcXhJBCBRQpEoiGZ8vrnSVON3awNxH593ibFqRItE-Wre8cz8yZU3TkgweEXhI8IZjwN8vJ0lg3oZjUE6wmmNZP0AnBSpRc0voInWCsSMlFpY7RaUpLnO9MqmfomHLBpeDsBM3nCyjg9wC-hbZYL8CHYbeGInTF7Nt1GSGtg09uC0UD7ieUvbuBwni7CLFYxzCA88X57PuH6UXRQuesA293z9HTzvQJXtydZ-jHp4_zy6ty9vXzl8vprLSci6FUopOK2LbuSNV1itdM0oaaRjUVB8It6YSkVUOINEq0NRDRMIwts7JrqRAVO0MXe9-F6fU6upWJOx2M01fTmR7fMKuIkEJuSWbP92yu-tcG0qBXLlnoe-MhbJImglMmqvrW9lEUS0EJZxl9fYAuwyb63HSmap7HzZnK1Ks7atOsoP1b6n0MGZB7wMaQUoROWzeYwQU_RON6TbAeE9dLPSaux8Q1VjonnqX0QHrv_qDo3V4EOZ2tg6jTbXLQugh20G1wD8vfH8ht77yzpr-BHaR_I9CJaqyvxz0c15DUmDBe02zw9v8Gj_3-B5Mn6M0
CitedBy_id crossref_primary_10_3390_biology11040612
crossref_primary_10_1038_cti_2017_20
crossref_primary_10_1016_j_jaci_2017_06_009
crossref_primary_10_1007_s10875_017_0401_y
crossref_primary_10_1111_bjh_18497
crossref_primary_10_1111_pai_12735
crossref_primary_10_1111_pai_12734
crossref_primary_10_3389_fimmu_2021_606099
crossref_primary_10_1186_s40164_021_00229_y
crossref_primary_10_3389_fimmu_2018_02397
crossref_primary_10_3389_fimmu_2019_00998
crossref_primary_10_3389_fimmu_2021_692219
crossref_primary_10_1007_s42000_020_00257_z
crossref_primary_10_3389_fimmu_2021_671755
crossref_primary_10_1007_s10875_024_01803_9
crossref_primary_10_1016_j_jaci_2021_04_005
crossref_primary_10_3389_fimmu_2020_574569
crossref_primary_10_1002_pbc_27260
crossref_primary_10_1007_s10875_018_0515_x
crossref_primary_10_1177_03946320221125591
crossref_primary_10_1182_blood_2021013496
crossref_primary_10_1016_j_clim_2019_04_011
crossref_primary_10_1016_j_jaci_2018_08_026
crossref_primary_10_35366_102982
crossref_primary_10_1007_s10875_016_0320_3
crossref_primary_10_3389_fimmu_2021_786516
crossref_primary_10_1007_s10875_017_0446_y
crossref_primary_10_1007_s10875_019_0594_3
crossref_primary_10_2337_db17_0040
crossref_primary_10_3389_fimmu_2024_1386260
crossref_primary_10_3389_fimmu_2020_01950
crossref_primary_10_1111_imr_12721
crossref_primary_10_3389_fimmu_2024_1409434
crossref_primary_10_1016_j_jaci_2019_12_896
crossref_primary_10_1182_blood_2017_11_814244
crossref_primary_10_1513_AnnalsATS_201601_079OC
crossref_primary_10_1007_s12016_018_8689_9
crossref_primary_10_1182_blood_2021014323
crossref_primary_10_1073_pnas_1901407116
crossref_primary_10_3390_cells11213353
crossref_primary_10_14785_lymphosign_2018_0011
crossref_primary_10_1016_j_jaci_2017_07_023
crossref_primary_10_1080_08820139_2020_1833029
crossref_primary_10_1186_s13023_017_0682_5
crossref_primary_10_1073_pnas_2202125119
crossref_primary_10_3389_fped_2020_599283
crossref_primary_10_1007_s10875_024_01770_1
crossref_primary_10_1007_s10875_017_0444_0
crossref_primary_10_1016_j_clim_2018_10_005
crossref_primary_10_3389_fped_2017_00049
crossref_primary_10_3389_fimmu_2020_01775
crossref_primary_10_12688_f1000research_21553_1
crossref_primary_10_1159_000503997
crossref_primary_10_1016_j_jaip_2019_11_039
crossref_primary_10_1186_s12887_023_04182_z
crossref_primary_10_1016_j_coi_2017_07_014
crossref_primary_10_1080_16078454_2022_2058736
crossref_primary_10_3389_fimmu_2021_619246
crossref_primary_10_1016_j_jaci_2018_10_026
crossref_primary_10_3389_fped_2019_00461
crossref_primary_10_1146_annurev_immunol_093019_124513
crossref_primary_10_1016_j_jaip_2019_04_011
crossref_primary_10_1172_JCI85647
crossref_primary_10_1016_j_clim_2016_03_006
crossref_primary_10_1038_s41467_024_53553_2
crossref_primary_10_1002_jcp_26772
crossref_primary_10_3389_fimmu_2018_00966
crossref_primary_10_1172_JCI129301
crossref_primary_10_3389_fped_2018_00121
crossref_primary_10_1007_s00431_018_3171_5
crossref_primary_10_3389_fimmu_2018_00720
crossref_primary_10_1007_s11926_019_0854_5
crossref_primary_10_1016_j_iac_2020_03_003
crossref_primary_10_3389_fped_2019_00353
crossref_primary_10_1111_sji_12922
crossref_primary_10_1038_s41390_019_0600_8
crossref_primary_10_1002_mgg3_1216
crossref_primary_10_3389_fimmu_2022_830961
crossref_primary_10_1007_s40272_016_0175_3
crossref_primary_10_3389_fimmu_2018_02012
crossref_primary_10_1080_08820139_2018_1446978
crossref_primary_10_1016_j_revmed_2016_10_388
crossref_primary_10_1016_j_jaci_2021_07_015
crossref_primary_10_1053_j_gastro_2016_12_016
crossref_primary_10_1016_j_jaci_2017_01_004
crossref_primary_10_1038_icb_2017_65
crossref_primary_10_1007_s10875_018_0524_9
crossref_primary_10_1038_s41467_023_38810_0
crossref_primary_10_17533_udea_acbi_v42n112a05
crossref_primary_10_1016_j_jecr_2022_100108
crossref_primary_10_1089_ped_2022_0088
crossref_primary_10_1016_j_jaip_2016_08_005
crossref_primary_10_1038_srep36568
crossref_primary_10_1016_j_jaip_2016_08_004
crossref_primary_10_3389_fimmu_2020_608024
crossref_primary_10_1186_s13023_022_02249_1
crossref_primary_10_1136_jmedgenet_2015_103690
crossref_primary_10_1007_s10875_022_01358_7
crossref_primary_10_1038_icb_2017_52
crossref_primary_10_1038_icb_2017_50
crossref_primary_10_1080_15513815_2022_2088912
crossref_primary_10_1016_j_coi_2021_05_010
crossref_primary_10_1016_j_imlet_2017_08_021
crossref_primary_10_2174_1871530319666190807161546
crossref_primary_10_1111_all_15331
crossref_primary_10_3389_fimmu_2017_00964
crossref_primary_10_1136_bcr_2022_250243
crossref_primary_10_3390_jcm10204729
crossref_primary_10_12998_wjcc_v9_i21_5873
crossref_primary_10_1038_s41584_024_01184_8
crossref_primary_10_1016_S1773_035X_23_00029_1
crossref_primary_10_3389_fped_2021_697706
crossref_primary_10_1097_MPH_0000000000001292
crossref_primary_10_1016_j_clim_2023_109302
crossref_primary_10_3390_ijms26062653
crossref_primary_10_1038_s41598_017_08543_4
crossref_primary_10_3389_fimmu_2021_806043
crossref_primary_10_1099_jmmcr_0_005167
crossref_primary_10_1080_09553002_2019_1577570
crossref_primary_10_3390_cancers15010081
crossref_primary_10_3389_fimmu_2017_00052
crossref_primary_10_1038_s41423_020_00626_z
crossref_primary_10_1172_jci_insight_122728
crossref_primary_10_1016_j_jaip_2020_10_057
crossref_primary_10_1097_ACI_0000000000000431
crossref_primary_10_1007_s13312_021_2175_9
crossref_primary_10_3389_fimmu_2022_881206
crossref_primary_10_3389_fped_2020_00042
crossref_primary_10_1016_j_jaci_2017_05_022
crossref_primary_10_1007_s00247_022_05361_3
crossref_primary_10_3389_fimmu_2021_704261
crossref_primary_10_1111_liv_15615
crossref_primary_10_1016_j_iac_2020_04_001
crossref_primary_10_3389_fped_2016_00098
crossref_primary_10_1080_07357907_2022_2153860
crossref_primary_10_1182_blood_2016_10_745174
crossref_primary_10_1016_j_jaip_2018_12_017
crossref_primary_10_1097_MPH_0000000000001708
crossref_primary_10_2174_1871530321666211209162834
crossref_primary_10_3389_fimmu_2024_1351076
crossref_primary_10_1007_s10875_020_00799_2
crossref_primary_10_3389_fimmu_2020_00338
crossref_primary_10_1007_s10875_019_00640_5
crossref_primary_10_1016_j_jaci_2023_03_026
crossref_primary_10_1038_s41385_021_00398_3
crossref_primary_10_1007_s10875_021_01177_2
crossref_primary_10_1182_blood_2016_04_712612
crossref_primary_10_15252_embr_201643689
crossref_primary_10_1097_MPH_0000000000002120
crossref_primary_10_1186_s40348_023_00167_1
crossref_primary_10_1136_gutjnl_2019_319850
crossref_primary_10_5812_ijp_84691
crossref_primary_10_1016_j_coi_2021_06_011
crossref_primary_10_1182_blood_2019000929
crossref_primary_10_3389_fped_2019_00295
crossref_primary_10_1097_ACI_0000000000000590
crossref_primary_10_14785_lymphosign_2023_0004
crossref_primary_10_1016_j_jaip_2019_06_011
crossref_primary_10_1002_ajmg_a_38480
crossref_primary_10_3389_fimmu_2018_01423
crossref_primary_10_1136_thoraxjnl_2021_217260
crossref_primary_10_1186_s12969_019_0388_4
crossref_primary_10_3389_fped_2021_662645
crossref_primary_10_1182_bloodadvances_2020002793
crossref_primary_10_1182_blood_2017_06_741033
crossref_primary_10_1080_08820139_2020_1770784
crossref_primary_10_1016_j_bj_2021_04_005
crossref_primary_10_1007_s00439_020_02131_9
crossref_primary_10_1038_s41525_021_00263_z
crossref_primary_10_1097_MOP_0000000000001331
crossref_primary_10_1007_s11096_023_01678_7
crossref_primary_10_1212_WNL_0000000000207609
crossref_primary_10_1007_s10875_023_01582_9
crossref_primary_10_1007_s10875_023_01604_6
crossref_primary_10_1016_j_jaip_2019_02_018
crossref_primary_10_1016_j_jaci_2018_02_055
crossref_primary_10_1007_s10875_019_00677_6
crossref_primary_10_1111_pai_14179
crossref_primary_10_1007_s10875_024_01759_w
crossref_primary_10_3389_fimmu_2022_944810
crossref_primary_10_1002_ppul_25373
crossref_primary_10_1172_JCI90831
crossref_primary_10_14785_lymphosign_2019_0015
crossref_primary_10_1016_j_htct_2022_03_003
crossref_primary_10_1016_j_humimm_2018_10_015
crossref_primary_10_1038_s41586_024_08346_4
crossref_primary_10_1111_cei_13600
crossref_primary_10_1007_s10620_020_06540_8
crossref_primary_10_1186_s40348_021_00114_y
crossref_primary_10_1016_j_jaci_2023_08_004
crossref_primary_10_3389_fimmu_2019_02742
crossref_primary_10_1159_000453263
crossref_primary_10_1016_j_aller_2019_07_011
Cites_doi 10.1038/nm.3746
10.1016/S0022-3476(97)70200-2
10.1016/j.jaci.2012.07.035
10.1186/ar2992
10.1016/j.ajhg.2012.04.015
10.1016/j.clim.2009.10.002
10.1111/tra.12069
10.1016/j.jaci.2012.05.043
10.1097/MIB.0000000000000266
10.1016/j.jaci.2014.10.019
10.1016/j.jaci.2014.10.048
10.1016/j.clim.2015.04.007
10.1016/B978-0-12-385991-4.00002-7
10.1126/science.aaa1663
ContentType Journal Article
Copyright 2015 American Academy of Allergy, Asthma & Immunology
American Academy of Allergy, Asthma & Immunology
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Copyright Elsevier Limited Jan 2016
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: 2015 American Academy of Allergy, Asthma & Immunology
– notice: American Academy of Allergy, Asthma & Immunology
– notice: Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
– notice: Copyright Elsevier Limited Jan 2016
– notice: Distributed under a Creative Commons Attribution 4.0 International License
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7SS
7T5
H94
K9.
NAPCQ
7X8
1XC
VOOES
DOI 10.1016/j.jaci.2015.09.025
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Entomology Abstracts (Full archive)
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Entomology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts

Entomology Abstracts
MEDLINE

MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-6825
EndPage 230
ExternalDocumentID oai_HAL_hal_03417878v1
3922004361
26768763
10_1016_j_jaci_2015_09_025
S0091674915013652
1_s2_0_S0091674915013652
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Bundesministerium für Bildung und Forschung
  grantid: 01E01303; 012X1306F; 8000805-3; 01GM1517C; 01GM1111B
  funderid: http://dx.doi.org/10.13039/501100002347
GroupedDBID ---
--K
--M
-~X
.1-
.55
.FO
.GJ
.XZ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
354
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8F7
8FE
8FH
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAFWJ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
ADXHL
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AFFNX
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
C45
CAG
CJTIS
COF
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDU
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LK8
LUGTX
M27
M41
MO0
N4W
N9A
O-L
O9-
O9~
OAUVE
OBH
ODZKP
OHH
OHT
OK0
OK1
OVD
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SJN
SPCBC
SSH
SSI
SSZ
T5K
TEORI
TWZ
UGJ
UNMZH
UV1
WH7
WOW
WUQ
X7M
XFW
YOC
YQI
YQJ
Z5R
ZGI
ZXP
ZY1
~02
~G-
~KM
AACTN
RIG
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7SS
7T5
H94
K9.
NAPCQ
7X8
1XC
VOOES
ID FETCH-LOGICAL-c667t-97f891cd5f14ff965382b2ab9b46e16c1f7824b118a97d5e17b300c3c8fd27743
IEDL.DBID .~1
ISSN 0091-6749
1097-6825
IngestDate Wed Jun 04 07:14:11 EDT 2025
Fri Jul 11 06:48:10 EDT 2025
Fri Jul 11 00:55:32 EDT 2025
Wed Aug 13 10:34:14 EDT 2025
Mon Jul 21 06:07:38 EDT 2025
Tue Jul 01 00:47:14 EDT 2025
Thu Apr 24 23:02:30 EDT 2025
Sun Apr 06 06:53:23 EDT 2025
Wed Apr 02 07:43:50 EDT 2025
Tue Aug 26 19:48:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords ALPS-Ph
ITP
LRBA
LPS-responsive beige-like anchor protein
Treg
IBD
hypogammaglobulinemia
ALPS
CVID
autoimmunity
common variable Immunodeficiency
enteropathy
primary immunodeficiency
IPEX
lymphoproliferation
HSCT
Autoimmune lymphoproliferative syndrome of undetermined genetic cause
Idiopathic thrombocytopenic purpura
Inflammatory bowel disease
Autoimmune lymphoproliferative syndrome
Regulatory T
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
Hematopoietic stem cell transplantation
Language English
License Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c667t-97f891cd5f14ff965382b2ab9b46e16c1f7824b118a97d5e17b300c3c8fd27743
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1509-8103
0000-0002-7925-1077
0000-0002-9259-1025
OpenAccessLink https://hal.science/hal-03417878
PMID 26768763
PQID 1756938639
PQPubID 105664
PageCount 8
ParticipantIDs hal_primary_oai_HAL_hal_03417878v1
proquest_miscellaneous_1762374574
proquest_miscellaneous_1760872163
proquest_journals_1756938639
pubmed_primary_26768763
crossref_citationtrail_10_1016_j_jaci_2015_09_025
crossref_primary_10_1016_j_jaci_2015_09_025
elsevier_sciencedirect_doi_10_1016_j_jaci_2015_09_025
elsevier_clinicalkeyesjournals_1_s2_0_S0091674915013652
elsevier_clinicalkey_doi_10_1016_j_jaci_2015_09_025
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-01-01
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: St. Louis
PublicationTitle Journal of allergy and clinical immunology
PublicationTitleAlternate J Allergy Clin Immunol
PublicationYear 2016
Publisher Elsevier Inc
Elsevier Limited
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier Limited
– name: Elsevier
References Revel-Vilk, Fischer, Keller, Nabhani, Gamez-Diaz, Rensing-Ehl (bib8) 2015; 159
Park, Levinson (bib11) 2010; 134
Charbonnier, Janssen, Chou, Ohsumi, Keles, Hsu (bib6) 2015; 135
Beck, Morbach, Beer, Stenzel, Tappe, Gattenlohner (bib9) 2010; 12
Yong, Thaventhiran, Grimbacher (bib12) 2011; 111
Cullinane, Schaffer, Huizing (bib1) 2013; 14
Alangari, Alsultan, Adly, Massaad, Kiani, Aljebreen (bib3) 2012; 130
Lo, Zhang, Lu, Zheng, Zhang, Kanellopoulou (bib13) 2015; 349
Lopez-Herrera, Tampella, Pan-Hammarstrom, Herholz, Trujillo-Vargas, Phadwal (bib2) 2012; 90
Seidel, Hirschmugl, Gamez-Diaz, Schwinger, Serwas, Deutschmann (bib7) 2015; 135
Serwas, Kansu, Santos-Valente, Kuloglu, Demir, Yaman (bib4) 2015; 21
Comans-Bitter, de Groot, van den Beemd, Neijens, Hop, Groeneveld (bib10) 1997; 130
Burns, Zenner, Plagnol, Curtis, Mok, Eisenhut (bib5) 2012; 130
Schubert, Bode, Kenefeck, Hou, Wing, Kennedy (bib14) 2014; 20
Cullinane (10.1016/j.jaci.2015.09.025_bib1) 2013; 14
Revel-Vilk (10.1016/j.jaci.2015.09.025_bib8) 2015; 159
Beck (10.1016/j.jaci.2015.09.025_bib9) 2010; 12
Park (10.1016/j.jaci.2015.09.025_bib11) 2010; 134
Yong (10.1016/j.jaci.2015.09.025_bib12) 2011; 111
Schubert (10.1016/j.jaci.2015.09.025_bib14) 2014; 20
Burns (10.1016/j.jaci.2015.09.025_bib5) 2012; 130
Lo (10.1016/j.jaci.2015.09.025_bib13) 2015; 349
Charbonnier (10.1016/j.jaci.2015.09.025_bib6) 2015; 135
Seidel (10.1016/j.jaci.2015.09.025_bib7) 2015; 135
Serwas (10.1016/j.jaci.2015.09.025_bib4) 2015; 21
Lopez-Herrera (10.1016/j.jaci.2015.09.025_bib2) 2012; 90
Alangari (10.1016/j.jaci.2015.09.025_bib3) 2012; 130
Comans-Bitter (10.1016/j.jaci.2015.09.025_bib10) 1997; 130
References_xml – volume: 159
  start-page: 84
  year: 2015
  end-page: 92
  ident: bib8
  article-title: Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation
  publication-title: Clin Immunol
– volume: 130
  start-page: 1428
  year: 2012
  end-page: 1432
  ident: bib5
  article-title: LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia
  publication-title: J Allergy Clin Immunol
– volume: 130
  start-page: 388
  year: 1997
  end-page: 393
  ident: bib10
  article-title: Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations
  publication-title: J Pediatr
– volume: 111
  start-page: 47
  year: 2011
  end-page: 107
  ident: bib12
  article-title: “A rose is a rose is a rose,” but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011?
  publication-title: Adv Immunol
– volume: 134
  start-page: 97
  year: 2010
  end-page: 103
  ident: bib11
  article-title: Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)
  publication-title: Clin Immunol
– volume: 135
  start-page: 1384
  year: 2015
  end-page: 1390
  ident: bib7
  article-title: Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency
  publication-title: J Allergy Clin Immunol
– volume: 12
  start-page: R74
  year: 2010
  ident: bib9
  article-title: Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment
  publication-title: Arthritis Res Ther
– volume: 14
  start-page: 749
  year: 2013
  end-page: 766
  ident: bib1
  article-title: The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease
  publication-title: Traffic
– volume: 90
  start-page: 986
  year: 2012
  end-page: 1001
  ident: bib2
  article-title: Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity
  publication-title: Am J Hum Genet
– volume: 135
  start-page: 217
  year: 2015
  end-page: 227.e9
  ident: bib6
  article-title: Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA
  publication-title: J Allergy Clin Immunol
– volume: 130
  start-page: 481
  year: 2012
  end-page: 488.e2
  ident: bib3
  article-title: LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency
  publication-title: J Allergy Clin Immunol
– volume: 21
  start-page: 40
  year: 2015
  end-page: 47
  ident: bib4
  article-title: Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype
  publication-title: Inflamm Bowel Dis
– volume: 349
  start-page: 436
  year: 2015
  end-page: 440
  ident: bib13
  article-title: AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
  publication-title: Science
– volume: 20
  start-page: 1410
  year: 2014
  end-page: 1416
  ident: bib14
  article-title: Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
  publication-title: Nat Med
– volume: 20
  start-page: 1410
  year: 2014
  ident: 10.1016/j.jaci.2015.09.025_bib14
  article-title: Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
  publication-title: Nat Med
  doi: 10.1038/nm.3746
– volume: 130
  start-page: 388
  year: 1997
  ident: 10.1016/j.jaci.2015.09.025_bib10
  article-title: Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations
  publication-title: J Pediatr
  doi: 10.1016/S0022-3476(97)70200-2
– volume: 130
  start-page: 1428
  year: 2012
  ident: 10.1016/j.jaci.2015.09.025_bib5
  article-title: LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2012.07.035
– volume: 12
  start-page: R74
  year: 2010
  ident: 10.1016/j.jaci.2015.09.025_bib9
  article-title: Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2992
– volume: 90
  start-page: 986
  year: 2012
  ident: 10.1016/j.jaci.2015.09.025_bib2
  article-title: Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2012.04.015
– volume: 134
  start-page: 97
  year: 2010
  ident: 10.1016/j.jaci.2015.09.025_bib11
  article-title: Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2009.10.002
– volume: 14
  start-page: 749
  year: 2013
  ident: 10.1016/j.jaci.2015.09.025_bib1
  article-title: The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease
  publication-title: Traffic
  doi: 10.1111/tra.12069
– volume: 130
  start-page: 481
  year: 2012
  ident: 10.1016/j.jaci.2015.09.025_bib3
  article-title: LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2012.05.043
– volume: 21
  start-page: 40
  year: 2015
  ident: 10.1016/j.jaci.2015.09.025_bib4
  article-title: Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/MIB.0000000000000266
– volume: 135
  start-page: 217
  year: 2015
  ident: 10.1016/j.jaci.2015.09.025_bib6
  article-title: Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2014.10.019
– volume: 135
  start-page: 1384
  year: 2015
  ident: 10.1016/j.jaci.2015.09.025_bib7
  article-title: Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2014.10.048
– volume: 159
  start-page: 84
  year: 2015
  ident: 10.1016/j.jaci.2015.09.025_bib8
  article-title: Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2015.04.007
– volume: 111
  start-page: 47
  year: 2011
  ident: 10.1016/j.jaci.2015.09.025_bib12
  article-title: “A rose is a rose is a rose,” but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011?
  publication-title: Adv Immunol
  doi: 10.1016/B978-0-12-385991-4.00002-7
– volume: 349
  start-page: 436
  year: 2015
  ident: 10.1016/j.jaci.2015.09.025_bib13
  article-title: AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
  publication-title: Science
  doi: 10.1126/science.aaa1663
SSID ssj0009389
Score 2.586252
Snippet LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein...
Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA...
Background LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency caused by biallelic mutations inLRBAthat abolish LRBA...
SourceID hal
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 223
SubjectTerms Adaptor Proteins, Signal Transducing - deficiency
Adaptor Proteins, Signal Transducing - genetics
Adaptor Proteins, Signal Transducing - metabolism
Adolescent
Allergy and Immunology
Apoptosis
autoimmunity
B-Lymphocytes - immunology
Child
Child, Preschool
common variable Immunodeficiency
enteropathy
Female
Genotype & phenotype
Hematopoietic Stem Cell Transplantation
Humans
hypogammaglobulinemia
Immunologic Deficiency Syndromes - drug therapy
Immunologic Deficiency Syndromes - immunology
Immunologic Deficiency Syndromes - metabolism
Immunologic Deficiency Syndromes - therapy
Immunosuppressive Agents - therapeutic use
Infant
Infections
Inflammatory bowel disease
Kinases
Life Sciences
LPS-responsive beige-like anchor protein
lymphoproliferation
Male
Mutation
Patients
Pharmaceutical sciences
Phenotype
primary immunodeficiency
Protein expression
Proteins
Rodents
Siblings
T-Lymphocytes - immunology
Title The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0091674915013652
https://www.clinicalkey.es/playcontent/1-s2.0-S0091674915013652
https://dx.doi.org/10.1016/j.jaci.2015.09.025
https://www.ncbi.nlm.nih.gov/pubmed/26768763
https://www.proquest.com/docview/1756938639
https://www.proquest.com/docview/1760872163
https://www.proquest.com/docview/1762374574
https://hal.science/hal-03417878
Volume 137
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIiEuiDeBUhnEAYRC7diO4-NSUS2wrRC0Um9WHg5NqZJqd9sjv52ZxNkKURaJYxxPYo_H4y_ON2OAV6XCVVHKIk61NLGqpI5tbmgnznJpZF3rhOKd9w_S6ZH6dKyPN2B3jIUhWmXw_YNP7711KNkJ2tw5bxqK8bVEobcIaYirRX5YKUNW_u7nFc3DymyAwFbEVDsEzgwcr9O8bIjepftcp3Rc9vWL040TYkn-DYL2S9HeXbgTMCSbDM28Bxu-vQ-39sNf8gdwiGPPxt1tRiSujnZaWVez2Zdv8TzQYi89K3zz3cdnzQ_PcPRPujnr8zY0LXs9-_p-8oZVnjJMUHjmQzja-3C4O43D6QlxmaZmGVtTZ1aUla6FqmuLY5ElRZIXtlCpF2kpagQHqsAPjNyaSnthCsl5KcusrhIEhfIRbLZd658Ak6oywpfoN1FCeW55YfCxJlOVz3niIxCj2lwZUovTCRdnbuSQnTpStSNVO24dqjqCtyuZ8yGxxtrachwNN4aMopNz6PfXSpnrpPwizNOFE26ROO7-sKUI9EryN3P85xtfoqmsOkS5u6eTmaMyjngBvWN2KSLYGi3JXbXE6BRtFQFjBC9Wt3Gu0w-cvPXdBdVJeUbZluTaOok0ShsVwePBSlfNSVL8uMQF5el_9u4Z3MarsAO1BZvL-YV_jphsWWz3k24bbk4-fp4e_AJi7C-0
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELZGJwEviN9kDDCIBxCKZsd2HD-WialjaYWgk_Zm5YfDsk3J1Hb7-7lrnEyIUSReE1_rnM_nL853nwl5X0hYFYXIw1gJHcpSqNBkGnfiDBNaVJWKsN55Oosnx_LriTrZIvt9LQzSKn3u73L6Olv7K3vem3uXdY01vgYp9AYgDXK1IA9vozqVGpHt8eHRZHajvSuSDgUbHqKBr53paF5nWVEjw0ut5U7xxOzb16c7p0iU_BsKXa9GBw_JAw8j6bjr6SOy5ZrH5O7Ufyh_QuYw_LTf4KbI42pxs5W2FU2__QgXnhl77Wju6p8uvKjPHYUAOG0XdC3dUDf0Q_r98_gjLR2KTGCF5lNyfPBlvj8J_QEKYRHHehUaXSWGF6WquKwqA8ORRHmU5SaXseNxwSvABzKHd4zM6FI5rnPBWCGKpCojwIXiGRk1beNeECpkqbkrIHWChXTMsFzDz-pEli5jkQsI791mC68ujodcXNieRnZm0dUWXW2ZseDqgHwabC47bY2NrUU_GravGoU8ZyH1b7TSt1m5pZ-qS8vtMrLM_hFOAVGD5W8R-c9_fAehMjwQyndPxqnFawwgAyTI5JoHZLePJHvTE61iiFXAjAF5O9yG6Y7fcLLGtVfYJmYJCi6JjW0ioaXSMiDPuygduhPF8H4Ja8rOfz7dG3JvMp-mNj2cHb0k9-GO35DaJaPV4sq9Aoi2yl_7KfgLu-gyZQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+extended+phenotype+of+LPS-responsive+beige-like+anchor+protein+%28LRBA%29+deficiency&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=G%C3%A1mez-D%C3%ADaz%2C+Laura&rft.au=August%2C+Dietrich&rft.au=Stepensky%2C+Polina&rft.au=Revel-Vilk%2C+Shoshana&rft.date=2016-01-01&rft.pub=Elsevier+Inc&rft.issn=0091-6749&rft.volume=137&rft.issue=1&rft.spage=223&rft.epage=230&rft_id=info:doi/10.1016%2Fj.jaci.2015.09.025&rft.externalDocID=S0091674915013652
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00916749%2FS0091674915X00029%2Fcov150h.gif